



**For immediate release**  
Lure, (France) February 7th, 2020

**MONTHLY INFORMATION REGARDING THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING OF THE SHARE CAPITAL**  
as per articles L233-8-II of « Code de Commerce » and 223.16 of the «Règlement Général de L’Autorité des Marchés Financiers »

| <b>Date</b> | <b>Previous total number of shares making of the share capital</b> | <b>Previous total number of voting rights</b> | <b>Change explanation</b>               | <b>New total number of shares making of the share</b> | <b>New total number of voting rights</b> |
|-------------|--|---|---|---|--|
| 31/01/2020  | 11.881.902   | 20 359 106                                    | Fluctuation in the double voting rights | 11.881.902  | 20 353 814                               |

**About Vetoquinol**

*Vetoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.*

*A family owned, pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.*

*Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vetoquinol employs 2.132 people world-wide.*

*Vetoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).*

*For more information: [www.vetoquinol.com](http://www.vetoquinol.com).*

**VETOQUINOL**  
Fanny TOILLON  
[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)